Latest Regulated Markets News

Memphasys Limited reported a net loss of AUD 4.94 million for FY25 while accelerating commercial efforts for its Felix System and advancing its RoXsta diagnostics platform.

Medical Developments International reports a strong FY25 with significant margin gains and strategic progress, setting the stage for accelerated Penthrox expansion in FY26.

Iress Limited reported a robust first half of 2025 with strong earnings growth and reduced leverage, driven by core business strength and strategic divestments. The company is poised to capitalize on regulatory tailwinds and technology demand in wealth and trading sectors.

Memphasys Limited pivots from development to commercial execution with its flagship IVF product Felix, targeting global markets through direct sales and recurring revenue streams.

xReality Group has secured a $2.1 million grant from the Australian Government to fast-track AI enhancements in its Operator XR tactical training platform, aiming to solidify its leadership in law enforcement and defense training worldwide.

Vitrafy Life Sciences reported a 75% increase in FY25 sales driven by aquaculture and human health sectors, progressing its cryopreservation technology towards commercialisation in both unregulated and regulated markets in FY26.

Althea Group Holdings announces the immediate resignation of founder and CEO Joshua Fegan, appointing Barry Katzman as interim CEO to steer the company’s THC beverage growth in North America.

Monash IVF Group has affirmed its compliance with ASX continuous disclosure rules following a clinical incident involving an embryo transfer error at its Clayton laboratory. The company clarified the materiality and timing of its disclosures in response to ASX inquiries.

EVE Health Group has initiated stability testing for its novel oral treatments targeting erectile dysfunction and dysmenorrhea, marking a crucial step toward regulatory approval in Australia. The company also finalizes its acquisition of Nextract, the developer behind these innovative formulations.

EVE Health Group has successfully passed all shareholder resolutions at its recent General Meeting, paving the way for its acquisition of Nextract Pty Ltd and announcing significant leadership changes.

Matsa Resources has advised shareholders to take no immediate action following Patronus Resources’ unsolicited takeover offer, with a formal recommendation expected soon.

Gyder Surgical, backed by Hydrix Ventures, has secured FDA 510(k) clearance for its innovative GYDER Hip System, opening the door to the lucrative U.S. market and increasing Hydrix’s investment value.